Edwards Lifesciences Corp
EW
$0.00
+1.47%
Edwards Lifesciences Corp designs and manufactures medical devices for advanced structural heart disease. It is a global leader in surgical and transcatheter heart valve technologies, with a strong international sales footprint.
EW
Edwards Lifesciences Corp
$0.00
Related headlines
Investment Opinion: Should I buy EW Today?
Based on a synthesis of the data, the objective assessment is a Hold. The company's strong fundamentals, growth trajectory, and leadership position are positive, but the current premium valuation and recent earnings margin pressure create a balanced risk/reward profile. Investors may find better entry points if the valuation moderates or if upcoming quarterly results demonstrate sustained margin improvement.
Sign up to view all
EW 12-Month Price Forecast
The outlook is balanced. Strong long-term fundamentals are countered by near-term valuation concerns and profitability questions. The base case, aligned with analyst EPS targets, suggests moderate upside potential from current levels, but significant multiple compression risk exists.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Edwards Lifesciences Corp's 12-month outlook, with a consensus price target around $0.00 and implied upside of — versus the current price.
Average Target
$0.00
9 analysts
Implied Upside
—
vs. current price
Analyst Count
9
covering this stock
Price Range
$0 - $0
Analyst target range
Wall Street analyst consensus shows an estimated average EPS of $4.56 for the upcoming period, with a revenue estimate of approximately $9.68 billion. Recent institutional ratings from firms like Goldman Sachs, BTIG, and Stifel maintain 'Buy' or 'Overweight' stances, while others like Truist and UBS have 'Hold' or 'Neutral' ratings. A specific consensus target price is not provided in the data.
Bulls vs Bears: EW Investment Factors
Edwards Lifesciences demonstrates strong underlying business growth and financial health, but faces headwinds from compressed margins and a premium valuation. The stock's recent pullback may present an opportunity, but hinges on earnings delivery to justify its multiples.
Bullish
- Strong Revenue Growth: Q4 2025 revenue grew 13.3% YoY, indicating robust demand.
- Solid Balance Sheet: Low debt-to-equity of 0.07 and high current ratio of 3.72.
- Analyst EPS Growth Expectations: Forward P/E of 24.2 vs trailing 46.4 implies strong earnings growth.
- Market Leadership: Global leader in structural heart disease devices with 60% international sales.
Bearish
- Premium Valuation: High trailing P/E of 46.4 and EV/EBITDA of 33.3 suggest overvaluation.
- Profitability Pressure: Q4 net income margin fell to 5.8% from 27.8% due to one-time items.
- Recent Underperformance: Stock down 7.4% in past month, underperforming S&P 500.
- High Operating Expenses: Selling & administrative costs remain elevated, pressuring margins.
EW Technical Analysis
The stock's overall trend over the past six months shows moderate volatility within a defined range, ending with a 4.5% gain over the period. The price peaked near $87.18 in early March 2026 but has since retreated. Over the short term, the stock has declined 7.4% in the past month and 6.1% over the past three months, underperforming the broader market as indicated by negative relative strength figures. The current price of $80.08 sits approximately 9% below its 52-week high of $87.89 and about 21% above its 52-week low of $65.94, positioning it in the upper-mid range of its yearly trading band.
Beta
0.93
0.93x market volatility
Max Drawdown
-12.7%
Largest decline past year
52-Week Range
$66-$88
Price range past year
Annual Return
+13.1%
Cumulative gain past year
| Period | EW Return | S&P 500 |
|---|---|---|
| 1m | -6.8% | -3.7% |
| 3m | -4.7% | -4.1% |
| 6m | +5.4% | -2.1% |
| 1y | +13.1% | +16.1% |
| ytd | -4.8% | -3.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
EW Fundamental Analysis
Revenue for Q4 2025 was $1.57 billion, representing a 13.3% year-over-year growth. However, profitability metrics showed pressure, with the net income margin for the quarter at 5.8%, a significant decline from the 27.8% margin in Q4 2024, primarily due to a large one-time gain in the prior year period. The company maintains a strong balance sheet with a low debt-to-equity ratio of 0.07 and a robust current ratio of 3.72, indicating ample liquidity. Operational efficiency, as measured by Return on Equity (ROE), stands at 10.4%, which is a solid level for the industry.
Quarterly Revenue
$1.6B
2025-12
Revenue YoY Growth
+0.13%
YoY Comparison
Gross Margin
+0.78%
Latest Quarter
Free Cash Flow
$1.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is EW Overvalued?
Given the company's positive net income, the primary valuation metric is the Price-to-Earnings (P/E) ratio. The trailing P/E is elevated at 46.4, while the forward P/E is 24.2, suggesting expectations for significant earnings growth. The EV/EBITDA ratio of 33.3 also indicates a premium valuation. Peer comparison data is not available in the provided inputs, so a relative assessment against industry averages cannot be made.
PE
46.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 3x~136x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
33.3x
Enterprise Value Multiple
Investment Risk Disclosure
The primary risks are valuation-related. The stock trades at a significant premium (P/E of 46.4, EV/EBITDA of 33.3), making it vulnerable to multiple compression if earnings growth disappoints or if market sentiment sours on high-multiple healthcare stocks. Operational risks include the potential for ongoing margin pressure from high R&D and SG&A spending, as seen in the Q4 2025 margin decline, though this was partly due to a non-recurring prior-year gain. Furthermore, as a company with 60% international sales, Edwards is exposed to foreign exchange volatility and geopolitical risks that could impact revenue. The technical picture shows recent weakness, with the stock underperforming the broader market over the past one and three months, indicating negative momentum that could persist.
FAQ
The key risks are valuation multiple contraction if earnings disappoint, continued pressure on net income margins (Q4 margin was 5.8%), and high operating expenses. Additionally, the stock has shown recent technical weakness, underperforming the S&P 500 over the past one and three months. Its significant international sales exposure also adds foreign exchange and geopolitical risk.
The 12-month outlook is mixed with a neutral base case. Using analyst EPS estimates of $4.56 and a forward P/E near 24x, a base case target range of $82-$92 is reasonable. A bull case (30% probability) could see the stock reach $95-$105 on strong execution, while a bear case (20% probability) could see it fall to $70-$78 on earnings misses or market downturns.
EW appears richly valued based on traditional metrics. Its trailing P/E of 46.4 and EV/EBITDA of 33.3 are high, indicating the market is paying a premium for future growth. The forward P/E of 24.2, based on analyst EPS estimates of $4.56, suggests the stock is fairly valued only if that aggressive earnings growth is achieved. It is not clearly undervalued.
EW is a Hold at its current price of $80.08. While the company is a leader in its field with strong revenue growth (13.3% YoY in Q4) and a robust balance sheet, its elevated trailing P/E ratio of 46.4 presents a valuation risk. The forward P/E of 24.2 suggests the market is pricing in significant earnings growth, which must materialize to justify the price.
EW is more suitable for long-term investors who can tolerate volatility and are confident in the company's multi-year growth story in structural heart devices. The premium valuation and recent underperformance make it a challenging short-term trade. Long-term holders can potentially benefit from secular demographic trends, but they must be patient for valuation to align with fundamentals.